Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467800 · ClinicalTrials.gov registry record · Phase 2
Study of Canakinumab in Patients With Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by John Mascarenhas.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 8
- Study locations
NCT05467800: Recruiting Phase 2 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by John Mascarenhas.
NCT05467800 is a Phase 2 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis that is actively recruiting participants, run by John Mascarenhas. The registered enrollment target is 14 participants, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (88% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05467800, a Phase 2 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, is actively recruiting participants, sponsored by John Mascarenhas.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle for a core study period of 8 cycles. Canakinumab will be given by subcutaneous injection (SC) injection at a starting dose of 200 mg (one 150 mg/mL syringe and one 50 mg/0.5 mL syringe) every 3 weeks. The interim analysis will be performed when the number of enrolled patients reaches 10. If no responses OR 4 or more patients have unacceptable toxicity, the study will not proceed to the second stage. If the total number of patients reaches the maximum sample size of 26, the treatment is deemed acceptable if the number of responses in the efficacy endpoint are greater than 3, and the number of toxicities are less than 7.
Primary Outcome
Efficacy of Canakinumab as measured by number of participant with response based on the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria. A response is considered any one of the following: complete response, partial response, or clinical improvement (inclusive of anemia response, spleen response, or symptom response).
Conditions Studied
Interventions
- DRUG Canakinumab
Study Locations (8)
North Carolina
- Atrium Health Levine Cancer Institute - Charlotte
- Wake Forest Baptist Health Comprehensive Cancer Center - Winston-Salem
Arizona
- Mayo Clinic Arizona - Phoenix
California
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles
Florida
- Moffitt Cancer Center - Tampa
Kansas
- The University of Kansas Cancer Center-Westwood - Westwood
New York
- Ruttenberg Treatment Center - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 2 |
What NCT05467800 shows while recruiting
NCT05467800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (88% lower).
The record links to 5 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Canakinumab is the first listed.
NCT05467800 lists 8 locations in 7 states (North Carolina, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT05467800 about?
NCT05467800 is a clinical study titled "Study of Canakinumab in Patients With Myelofibrosis". This is an open label, multicenter, phase 2 trial of Canakinumab in patients with primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF). Eligible patients will receive Canakinumab administered as a subcutaneous injection on day 1 of a 21 day cycle f...
What is the current status of trial NCT05467800?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2022-08-02. Estimated completion is 2027-07-01.
What conditions does trial NCT05467800 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF.
What interventions are being tested in trial NCT05467800?
The interventions under investigation include: Canakinumab (DRUG).
Who is sponsoring clinical trial NCT05467800?
This trial is sponsored by John Mascarenhas, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05467800 being conducted?
This trial has 8 study locations across Arizona, California, Florida, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05467800's enrollment target sits among peer trials
14 30th of 30 higher than 1 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy